A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Vismodegib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 30 May 2014 Primary endpoint 'Progression-free-survival-rate' has not been met according to the results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 01 May 2012 Planned end date changed from 1 May 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.